Researchers want to know whether a sleeping pill reduces suicidal thoughts in depressed patients with insomnia.
“The more we look at it, the more it looks like insomnia by itself is a predictor of suicide so the next question becomes: Why not treat insomnia strategically as a focus of care and see if that reduces suicidal thinking,” said Dr W. Vaughn McCall, Chair of the Medical College of Georgia Department of Psychiatry and Health Behavior at Georgia Regents University.
McCall is principal investigator on a $1.2 million National Institute of Mental Health grant to objectively assess patient response to this strategy. The study at GRU, Duke University, and the University of Wisconsin is enrolling 138 adults over 4 years. To help ensure their safety, all participants will receive the anti-depressant fluoxetine for the 8-week trial while half will also get the sedative-hypnotic zolpidem.
It’s a complex treatment conundrum that the study hopes to unravel. Some physicians are worried about giving sleeping pills to people with suicidal thoughts. “We are faced very commonly with a patient who is not sleeping, is depressed, is suicidal, and the treating physician is understandably concerned about giving that patient sleeping pills,” McCall said.
In fact, some sleep experts routinely condemn sleeping pills, saying the pills are potentially deadly, independent of suicide. Other people with chronic insomnia never seek professional help, trying home or natural remedies while their negative thoughts about sleep escalate. If they do seek medical care as problems mount, they may find themselves with a doctor hesitant or even adamant about hypnotics, McCall said.
If researchers can show a direct link between insomnia treatment and reduced suicidal thinking, it could help mainstream targeted drug therapy as well as non-drug approaches such as cognitive behavior therapy, a structured talk therapy that targets faulty thinking such as “I will never sleep again,” said McCall, who also uses this approach.